Showing results (41-50 of 329) with videos related to
Sort By:
Pageof 33
Clinical Cardiology|March 2, 2006
Ezetimibe: rationale and role in the management of hypercholesterolemiaLeonid Yatskar, Edward A Fisher, Arthur SchwartzbardArteriosclerosis, Thrombosis, and Vascular Biology|January 11, 2014
Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in miceBernd Hewing, Saj Parathath, Tessa Barrett, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|April 21, 2012
Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibitionNicola Wilck, Mandy Fechner, Henryk Dreger, et al.The Journal of Biological Chemistry|September 10, 2003
Apolipoprotein B100 exit from the endoplasmic reticulum (ER) is COPII-dependent, and its lipidation to very low density lipoprotein occurs post-ERViktoria Gusarova, Jeffrey L Brodsky, Edward A FisherPediatric Endocrinology Reviews : PER|December 18, 2007
Therapeutic approach to childhood hypercholesterolemiaRaanan Shamir, Jonathan E Feig, Edward A FisherCurrent Drug Targets|March 14, 2008
Atheroprotective effects of HDL: beyond reverse cholesterol transportJonathan E Feig, Raanan Shamir, Edward A FisherCirculation Research|May 10, 2019
HDL and Reverse Cholesterol TransportMireille Ouimet, Tessa J Barrett, Edward A FisherTrends in Immunology|April 4, 2006
TLR signaling and trapped vascular dendritic cells in the development of atherosclerosisTerence M Doherty, Edward A Fisher, Moshe ArditiMolecular Biology of the Cell|December 15, 2021
Hsp40s play distinct roles during the initial stages of apolipoprotein B biogenesisDeepa Kumari, Edward A Fisher, Jeffrey L BrodskyCurrent Opinion in Pediatrics|May 1, 2002
Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and managementJeffrey M Saland, Henry Ginsberg, Edward A FisherPageof 33